The fibrosis-cell death axis in heart failure

Cardiac stress can induce morphological, structural and functional changes of the heart, referred to as cardiac remodeling. Myocardial infarction or sustained overload as a result of pathological causes such as hypertension or valve insufficiency may result in progressive remodeling and finally lead to heart failure (HF). Whereas pathological and physiological (exercise, pregnancy) overload both stimulate cardiomyocyte growth (hypertrophy), only pathological remodeling is characterized by increased deposition of extracellular matrix proteins, termed fibrosis, and loss of cardiomyocytes by necrosis, apoptosis and/or phagocytosis. HF is strongly associated with age, and cardiomyocyte loss and fibrosis are typical signs of the aging heart. Fibrosis results in stiffening of the heart, conductivity problems and reduced oxygen diffusion, and is associated with diminished ventricular function and arrhythmias. As a consequence, the workload of cardiomyocytes in the fibrotic heart is further augmented, whereas the physiological environment is becoming less favorable. This causes additional cardiomyocyte death and replacement of lost cardiomyocytes by fibrotic material, generating a vicious cycle of further decline of cardiac function. Breaking this fibrosis-cell death axis could halt further pathological and age-related cardiac regression and potentially reverse remodeling. In this review, we will describe the interaction between cardiac fibrosis, cardiomyocyte hypertrophy and cell death, and discuss potential strategies for tackling progressive cardiac remodeling and HF.

[1]  G. Dorn Nix Nought Nothing: fairy tale or real deal. , 2011, Journal of molecular and cellular cardiology.

[2]  T. Borg,et al.  Structural and functional characterisation of cardiac fibroblasts. , 2005, Cardiovascular research.

[3]  J. Molkentin,et al.  Molecular basis of physiological heart growth: fundamental concepts and new players , 2012, Nature Reviews Molecular Cell Biology.

[4]  B. Hinz,et al.  Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. , 2001, Molecular biology of the cell.

[5]  Gary R. Grotendorst,et al.  Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  P. Dijke,et al.  Extracellular control of TGFβ signalling in vascular development and disease , 2007, Nature Reviews Molecular Cell Biology.

[7]  Katherine E Yutzey,et al.  Development of heart valve leaflets and supporting apparatus in chicken and mouse embryos , 2004, Developmental dynamics : an official publication of the American Association of Anatomists.

[8]  R. Belardinelli,et al.  Waltz Dancing in Patients With Chronic Heart Failure: New Form of Exercise Training , 2008, Circulation. Heart failure.

[9]  Transforming growth factor-β: governing the transition from inflammation to fibrosis in heart failure with preserved left ventricular function. , 2011, Circulation. Heart failure.

[10]  R. Hajjar,et al.  Targeting sarcoplasmic reticulum calcium ATPase by gene therapy. , 2013, Human gene therapy.

[11]  J. S. Janicki,et al.  Interleukin 6 Mediates Myocardial Fibrosis, Concentric Hypertrophy, and Diastolic Dysfunction in Rats , 2010, Hypertension.

[12]  E. McCall,et al.  Cardiac Sodium Channels as Targets for New Inotropic Agents , 1998, Heart Failure Reviews.

[13]  B. Hinz,et al.  Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. , 2012, The American journal of pathology.

[14]  E. Agapitos,et al.  Depressed coronary flow reserve is associated with decreased myocardial capillary density in patients with heart failure due to idiopathic dilated cardiomyopathy. , 2008, Journal of the American College of Cardiology.

[15]  Hans L Hillege,et al.  Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction , 2010, Annals of medicine.

[16]  T. Doetschman,et al.  Fibroblast Growth Factor 2 Mediates Isoproterenol-induced Cardiac Hypertrophy through Activation of the Extracellular Regulated Kinase. , 2010, Molecular and cellular pharmacology.

[17]  A. Wu,et al.  High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure , 2011, Circulation. Heart failure.

[18]  Who did what? , 2004 .

[19]  A. Voors,et al.  Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure , 2016, Expert opinion on investigational drugs.

[20]  O. Frazier,et al.  Fibrosis and heart failure , 2014, Heart Failure Reviews.

[21]  J. McMullen,et al.  Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. , 2010, Pharmacology & therapeutics.

[22]  A. Desmoulière,et al.  Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts , 1993, The Journal of cell biology.

[23]  E. B. Smith Quantitative and qualitative comparison of the lipids in platelets, aortic intima, and mural thrombi. , 1967, Cardiovascular research.

[24]  D. Rifkin Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability. , 2005, The Journal of biological chemistry.

[25]  C. Long,et al.  The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. , 2005, Annual review of pharmacology and toxicology.

[26]  P. Hordijk Localizing cellular housekeeping , 2011, Nature Reviews Molecular Cell Biology.

[27]  Ivan C. Gerling,et al.  Myofibroblast-mediated mechanisms of pathological remodelling of the heart , 2013, Nature Reviews Cardiology.

[28]  S. Kauppinen,et al.  Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. , 2010, The Journal of clinical investigation.

[29]  Douglas E. Vaughan,et al.  MiR-125b Is Critical for Fibroblast-to-Myofibroblast Transition and Cardiac Fibrosis , 2016, Circulation.

[30]  M. Yacoub,et al.  Functional crosstalk between cardiac fibroblasts and adult cardiomyocytes by soluble mediators. , 2015, Cardiovascular research.

[31]  J. Schaper,et al.  Progression From Compensated Hypertrophy to Failure in the Pressure-Overloaded Human Heart: Structural Deterioration and Compensatory Mechanisms , 2003, Circulation.

[32]  M. Hori,et al.  Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  W. Rottbauer,et al.  MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts , 2008, Nature.

[34]  Bertram Pitt,et al.  Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial Fibrogenesis , 2013, Circulation. Heart failure.

[35]  A. Desmoulière,et al.  Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. , 1995, The American journal of pathology.

[36]  G. Mancia,et al.  Effects of cardiac denervation on blood pressure and heart rate during natural sleep in the cat. , 1968, Cardiovascular research.

[37]  S. Rohr,et al.  Abolishing Myofibroblast Arrhythmogeneicity by Pharmacological Ablation of &agr;-Smooth Muscle Actin Containing Stress Fibers , 2011, Circulation research.

[38]  J. Goergen,et al.  The collagen receptor DDR2 regulates proliferation and its elimination leads to dwarfism , 2001, EMBO reports.

[39]  Zoltan Szalay,et al.  Structural correlate of atrial fibrillation in human patients. , 2002, Cardiovascular research.

[40]  D. Fukai,et al.  Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. , 1998, Journal of the American College of Cardiology.

[41]  P. Liton,et al.  Cathepsin B Is Up-Regulated and Mediates Extracellular Matrix Degradation in Trabecular Meshwork Cells Following Phagocytic Challenge , 2013, PloS one.

[42]  M. Anderton,et al.  Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors , 2011, Toxicologic pathology.

[43]  E. Feigl,et al.  Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function. , 2007, The American journal of pathology.

[44]  Hui-Hua Li,et al.  Macrophage-Stimulated Cardiac Fibroblast Production of IL-6 Is Essential for TGF β/Smad Activation and Cardiac Fibrosis Induced by Angiotensin II , 2012, PloS one.

[45]  M. Hori,et al.  Progression of heart failure was suppressed by inhibition of apoptosis signal-regulating kinase 1 via transcoronary gene transfer. , 2007, Journal of the American College of Cardiology.

[46]  Jeffrey E. Thatcher,et al.  Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis , 2008, Proceedings of the National Academy of Sciences.

[47]  J. Guerrero,et al.  Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Juerg Schwitter,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[49]  Z. Werb,et al.  Remodelling the extracellular matrix in development and disease , 2014, Nature Reviews Molecular Cell Biology.

[50]  J Michael DiMaio,et al.  Making steady progress on direct cardiac reprogramming toward clinical application. , 2013, Circulation research.

[51]  G. Kung,et al.  Programmed necrosis, not apoptosis, in the heart. , 2011, Circulation research.

[52]  G. Gabbiani,et al.  The myofibroblast in wound healing and fibrocontractive diseases , 2003, The Journal of pathology.

[53]  N. Turner Effects of interleukin-1 on cardiac fibroblast function: relevance to post-myocardial infarction remodelling. , 2014, Vascular pharmacology.

[54]  M. Dvoráková,et al.  Effective myofibroblast dedifferentiation by concomitant inhibition of TGF-β signaling and perturbation of MAPK signaling. , 2013, European journal of cell biology.

[55]  R. D. de Boer,et al.  Identification of hypertrophy- and heart failure-associated genes by combining in vitro and in vivo models. , 2012, Physiological genomics.

[56]  J. Teerlink A novel approach to improve cardiac performance: cardiac myosin activators , 2009, Heart Failure Reviews.

[57]  R. Kalluri,et al.  Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. , 2013, American journal of physiology. Cell physiology.

[58]  J. Erler,et al.  Matrix cross-linking lysyl oxidases are induced in response to myocardial infarction and promote cardiac dysfunction. , 2016, Cardiovascular research.

[59]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[60]  N. Frangogiannis,et al.  The role of IL-1 in the pathogenesis of heart disease , 2009, Archivum Immunologiae et Therapiae Experimentalis.

[61]  V. Weaver,et al.  Extracellular matrix assembly: a multiscale deconstruction , 2014, Nature Reviews Molecular Cell Biology.

[62]  Y. Pinto,et al.  Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. , 2011, Cardiovascular research.

[63]  J. Molkentin,et al.  ASK1 Regulates Cardiomyocyte Death but Not Hypertrophy in Transgenic Mice , 2009, Circulation research.

[64]  J. Horowitz,et al.  Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. , 2006, Proceedings of the American Thoracic Society.

[65]  J. Molkentin,et al.  Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. , 2010, Circulation.

[66]  G. Gabbiani,et al.  The cellular derivation and the life span of the myofibroblast. , 1996, Pathology, research and practice.

[67]  G. Dorn,et al.  Distinct Pathways Regulate Proapoptotic Nix and BNip3 in Cardiac Stress* , 2006, Journal of Biological Chemistry.

[68]  K. Red-Horse,et al.  Developmental Heterogeneity of Cardiac Fibroblasts Does Not Predict Pathological Proliferation and Activation , 2014, Circulation research.

[69]  Xueli Yuan,et al.  Endothelial-to-mesenchymal transition contributes to cardiac fibrosis , 2007, Nature Medicine.

[70]  D. Kaye,et al.  Role of transiently altered sarcolemmal membrane permeability and basic fibroblast growth factor release in the hypertrophic response of adult rat ventricular myocytes to increased mechanical activity in vitro. , 1996, The Journal of clinical investigation.

[71]  David S. Rogers,et al.  Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation. , 2009, American Journal of Respiratory Cell and Molecular Biology.

[72]  A. Nag,et al.  Study of non-muscle cells of the adult mammalian heart: a fine structural analysis and distribution. , 1980, Cytobios.

[73]  Joseph A. Hill,et al.  Pathological Ventricular Remodeling: Mechanisms Part 1 of 2 , 2013, Circulation.

[74]  Z. Werb,et al.  Extracellular matrix degradation and remodeling in development and disease. , 2011, Cold Spring Harbor perspectives in biology.

[75]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[76]  J. McMullen,et al.  The athlete's heart vs. the failing heart: can signaling explain the two distinct outcomes? , 2011, Physiology.

[77]  Gang Liu,et al.  New Insights into the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis , 2011, Drugs.

[78]  R. Ferrari,et al.  The role of TNF in cardiovascular disease. , 1999, Pharmacological research.

[79]  Stephanie L. K. Bowers,et al.  Cardiac Fibroblast: The Renaissance Cell , 2009, Circulation research.

[80]  A. Papavassiliou,et al.  The role of inflammation in heart failure: new therapeutic approaches. , 2011, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[81]  M. Harmsen,et al.  Bone marrow‐derived myofibroblasts contribute functionally to scar formation after myocardial infarction , 2008, The Journal of pathology.

[82]  B. Hinz Formation and function of the myofibroblast during tissue repair. , 2007, The Journal of investigative dermatology.

[83]  Barry Greenberg,et al.  Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca2+-ATPase in Patients With Advanced Heart Failure , 2011, Circulation.

[84]  A. Hoes,et al.  Clinical epidemiology of heart failure , 2007, Heart.

[85]  K. Weber,et al.  Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.

[86]  F. Strutz,et al.  TGF-beta 1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2). , 2001, Kidney international.

[87]  Francis G Spinale,et al.  Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. , 2007, Physiological reviews.

[88]  M. Berry,et al.  Inhibition of Matrix Metalloproteinase Activity by TIMP-1 Gene Transfer Effectively Treats Ischemic Cardiomyopathy , 2004, Circulation.

[89]  J. Cohn,et al.  C-Reactive Protein in Heart Failure: Prognostic Value and the Effect of Valsartan , 2005, Circulation.

[90]  Paul H. Huang,et al.  Discoidin Domain Receptors: Unique Receptor Tyrosine Kinases in Collagen-mediated Signaling* , 2013, The Journal of Biological Chemistry.

[91]  Thomas H Everett,et al.  Atrial fibrosis and the mechanisms of atrial fibrillation. , 2007, Heart rhythm.

[92]  Nag Ac,et al.  Study of non-muscle cells of the adult mammalian heart: a fine structural analysis and distribution. , 1980 .

[93]  Dean Sheppard,et al.  TGF-β activation and function in immunity. , 2014, Annual review of immunology.

[94]  P. Doevendans,et al.  Myocyte apoptosis in heart failure. , 2005, Cardiovascular research.

[95]  R. Wachter,et al.  Galectin‐3 in patients with heart failure with preserved ejection fraction: results from the Aldo‐DHF trial , 2015, European journal of heart failure.

[96]  Xiaohong Yan,et al.  Antagonism of endothelin-1 inhibits hypoxia-induced apoptosis in cardiomyocytes. , 2008, Canadian journal of physiology and pharmacology.

[97]  B. Morgan,et al.  Cardiac myosin activation part 1: from concept to clinic. , 2011, Journal of molecular and cellular cardiology.

[98]  Young-Jae Nam,et al.  Heart repair by cardiac reprogramming , 2013, Nature Medicine.

[99]  Richard T. Lee,et al.  Intramyocardial Fibroblast Myocyte Communication , 2010, Circulation research.

[100]  Robert H. Anderson,et al.  Lineage and Morphogenetic Analysis of the Cardiac Valves , 2004, Circulation research.

[101]  P. ten Dijke,et al.  Regulation of endothelial cell plasticity by TGF-β , 2011, Cell and Tissue Research.

[102]  C. Tschöpe,et al.  Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase? , 2013, Cardiovascular research.

[103]  K. Otsu,et al.  Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. , 2010, The Journal of clinical investigation.

[104]  R. D. de Boer,et al.  Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. , 2013, European heart journal.

[105]  E Sowton,et al.  Effect of changes in ventricular rate on cardiac output and central pressures at rest and during exercise in patients with artificial pacemakers. , 1967, Cardiovascular research.

[106]  N. Frangogiannis,et al.  The pathogenesis of cardiac fibrosis , 2013, Cellular and Molecular Life Sciences.

[107]  S. Elmore Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.

[108]  A. Larue,et al.  Hematopoietic origin of fibroblasts/myofibroblasts: Its pathophysiologic implications. , 2006, Blood.

[109]  S. Nattel,et al.  Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. , 2008, Journal of the American College of Cardiology.

[110]  B. Bozkurt,et al.  Basic mechanisms in heart failure: the cytokine hypothesis. , 1996, Journal of cardiac failure.

[111]  M. Yacoub,et al.  Increased expression of extracellular matrix regulators TIMP1 and MMP1 in deteriorating heart failure. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[112]  P. Parker,et al.  Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes. The potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy. , 1994, The Journal of biological chemistry.

[113]  D. Brenner,et al.  Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. , 2014, The Journal of clinical investigation.

[114]  F. Meijler Atrial fibrillation: a new look at an old arrhythmia. , 1983, Journal of the American College of Cardiology.

[115]  B. Dorhout,et al.  Omecamtiv Mecarbil : a Novel Cardiac Myosin Activator for the Treatment of Heart Failure , 2018 .

[116]  S. Hazen,et al.  Plasma myeloperoxidase levels in patients with chronic heart failure. , 2006, The American journal of cardiology.

[117]  P. ten Dijke,et al.  Extracellular control of TGFbeta signalling in vascular development and disease. , 2007, Nature reviews. Molecular cell biology.

[118]  J. Iredale,et al.  Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. , 1998, The Journal of clinical investigation.

[119]  Arantxa González,et al.  Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal. , 2015, Journal of the American College of Cardiology.

[120]  Niels Voigt,et al.  Cellular and Molecular Electrophysiology of Atrial Fibrillation Initiation, Maintenance, and Progression , 2014, Circulation research.

[121]  N. Frangogiannis,et al.  Aging and Cardiac Fibrosis. , 2011, Aging and disease.

[122]  C. Stehouwer,et al.  Microvascular Dysfunction: A Potential Mechanism in the Pathogenesis of Obesity‐associated Insulin Resistance and Hypertension , 2012, Microcirculation.

[123]  M. Hori,et al.  Apoptosis signal-regulating kinase 1 is involved not only in apoptosis but also in non-apoptotic cardiomyocyte death. , 2005, Biochemical and biophysical research communications.

[124]  S. Hazen,et al.  Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation , 2010, Nature Medicine.

[125]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[126]  V. Petrov,et al.  Reversible and irreversible differentiation of cardiac fibroblasts , 2013, Cardiovascular research.

[127]  J. Januzzi,et al.  Biomarkers and diagnostics in heart failure. , 2013, Biochimica et biophysica acta.

[128]  Cheuk-Man Yu,et al.  miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-β/Smad3 signaling. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[129]  G. Dorn,et al.  Nix-Mediated Apoptosis Links Myocardial Fibrosis, Cardiac Remodeling, and Hypertrophy Decompensation , 2008, Circulation.

[130]  A. Criollo,et al.  Cardiomyocyte death: mechanisms and translational implications , 2011, Cell Death and Disease.

[131]  R. Körfer,et al.  The structural examination of myocardial samples from patients with end-stage heart failure supported by ventricular assist devices using electron microscopy and amino acid analysis reveals low degree of reverse remodeling. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[132]  S. Jimenez,et al.  Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. , 2011, The American journal of pathology.

[133]  I. Sjaastad,et al.  Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5. , 2014, Journal of molecular and cellular cardiology.

[134]  B. Hinz,et al.  Myofibroblasts and mechano-regulation of connective tissue remodelling , 2002, Nature Reviews Molecular Cell Biology.

[135]  B. Ebert,et al.  Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. , 2015, Cell stem cell.

[136]  Xiaoxia Qi,et al.  Heart repair by reprogramming non-myocytes with cardiac transcription factors , 2012, Nature.

[137]  V. Roger Epidemiology of Heart Failure , 2013, Circulation research.

[138]  T. Pedrazzini,et al.  Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. , 2001, The Journal of clinical investigation.

[139]  S. Vatner,et al.  Novel mechanisms for caspase inhibition protecting cardiac function with chronic pressure overload , 2012, Basic Research in Cardiology.

[140]  Don C Rockey,et al.  Fibrosis--a common pathway to organ injury and failure. , 2015, The New England journal of medicine.

[141]  I. Komuro,et al.  Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts. , 2015, American journal of physiology. Heart and circulatory physiology.

[142]  Qing-Qing Wu,et al.  Cathepsin B deficiency attenuates cardiac remodeling in response to pressure overload via TNF-α/ASK1/JNK pathway. , 2015, American journal of physiology. Heart and circulatory physiology.

[143]  S. Friedman,et al.  Modulation of cardiac fibrosis by Krüppel-like factor 6 through transcriptional control of thrombospondin 4 in cardiomyocytes. , 2015, Cardiovascular research.

[144]  M. Centrella,et al.  Regulation of proliferative response of cardiac fibroblasts by transforming growth factor-beta 1. , 1996, Journal of molecular and cellular cardiology.

[145]  D. Rifkin Latent Transforming Growth Factor-β (TGF-β) Binding Proteins: Orchestrators of TGF-β Availability* , 2005, Journal of Biological Chemistry.

[146]  Stephan von Haehling,et al.  Inflammatory mediators in chronic heart failure: an overview , 2004, Heart.

[147]  W. Linke,et al.  Syndecan-4 is a key determinant of collagen cross-linking and passive myocardial stiffness in the pressure-overloaded heart. , 2015, Cardiovascular research.

[148]  S. Goldstein,et al.  Ventricular remodelling: consequences and therapy. , 1993, European heart journal.

[149]  I. V. Van Gelder,et al.  Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation. , 2011, Cardiovascular research.

[150]  Sander Verheule,et al.  Increased Vulnerability to Atrial Fibrillation in Transgenic Mice With Selective Atrial Fibrosis Caused by Overexpression of TGF-β1 , 2004, Circulation research.

[151]  Thomas Thum,et al.  Noncoding RNAs and myocardial fibrosis , 2014, Nature Reviews Cardiology.